2. Anti-infection Immunology/Inflammation NF-κB MAPK/ERK Pathway Membrane Transporter/Ion Channel Cell Cycle/DNA Damage PI3K/Akt/mTOR
  3. Parasite Fungal NO Synthase Interleukin Related NF-κB p38 MAPK Na+/K+ ATPase PERK JNK Akt PI3K
  4. Strictosamide

Strictosamide is a compound that can be isolated from Nauclea officinalis. Strictosamide has various activities such as anti-inflammatory, analgesic, anti-Plasmodium, antifungal, and promoting wound healing.

For research use only. We do not sell to patients.

Strictosamide Chemical Structure

Strictosamide Chemical Structure

CAS No. : 23141-25-5

Size Price Stock Quantity
1 mg In-stock
5 mg In-stock
10 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Strictosamide Related Antibodies

Top Publications Citing Use of Products

View All Parasite Isoform Specific Products:

View All Isoforms
Amebae Coccidia Leishmania Mite Plasmodium Toxoplasma Trypanosoma Schistosome

View All NO Synthase Isoform Specific Products:

View All Isoforms
nNOS iNOS eNOS

View All Interleukin Related Isoform Specific Products:

View All Isoforms
IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22

View All NF-κB Isoform Specific Products:

View All Isoforms
NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

View All p38 MAPK Isoform Specific Products:

View All Isoforms
p38 MAPK p38α p38β MAPK13 p38δ p38γ

View All JNK Isoform Specific Products:

View All Isoforms
JNK1 JNK2 JNK3 JNK

View All Akt Isoform Specific Products:

View All Isoforms
Akt Akt1 Akt2 Akt3

View All PI3K Isoform Specific Products:

View All Isoforms
PI3Kα PI3Kβ PI3Kγ PI3Kδ PI3KC2α PI3KC2β PI3KC2γ Vps34 PI3K PI3KC3 p120γ

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Strictosamide is a compound that can be isolated from Nauclea officinalis. Strictosamide has various activities such as anti-inflammatory, analgesic, anti-Plasmodium, antifungal, and promoting wound healing[1][2][3][4][5].

Cellular Effect
Cell Line Type Value Description References
A549 IC50
> 80 μM
Compound: 21
Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
[PMID: 31804070]
HepG2 IC50
> 80 μM
Compound: 21
Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
[PMID: 31804070]
MCF7 IC50
> 80 μM
Compound: 21
Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
[PMID: 31804070]
In Vitro

Strictosamide (0-200 μM; 24 h) can inhibit the production of NO, TNF-α, and IL-1β, as well as the expression of iNOS in LPS (HY-D1056)-treated RAW 264.7 cells. The mechanism involves the inhibition of the NF-κB and MAPK pathways[1].
Strictosamide (0.25-2 mg/mL) can inhibit the Mg2+-ATPase activity in isolated kidneys[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Strictosamide Related Antibodies

Western Blot Analysis[1]

Cell Line: LPS (HY-D1056)-treated RAW 264.7 cells
Concentration: 0, 25, 50, 100 and 200 µM
Incubation Time: 24 h
Result: Markedly decreased the expressions of p-p65, p-IκBα and p-IKKα in NF-κB signaling pathways.
Significantly decreased the phosphorylation of p38, ERK and JNK in MAPK signaling pathways.
In Vivo

Strictosamide (50-200 mg/kg; intraperitoneal injection; single dose) can increase the Na+, K+-ATPase activity in the mouse brain and inhibit the Mg2+-ATPase activity in the mouse kidneys[2].
Strictosamide (10-40 mg/kg; intravenous injection; twice a day; 3 days) has anti-inflammatory and analgesic effects in multiple mouse models[3].
Strictosamide (0.5-1.5 mg/kg; topical application; twice a day; 8 days) has a wound-healing-promoting effect in a rat wound model. The mechanism involves the activation of the PI3K/AKT signaling pathway[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: ICR mice, weighing 18-22 g[3]
Dosage: 10, 20 and 40 mg/kg
Administration: Intravenous injection; twice a day; 3 days
Result: Obviously decreased the 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced mice ear edema (24.7 and 28.1% inhibition, respectively) at 20 and 40 mg/kg.
Significantly inhibited acetic acid (HY-Y0319)-stimulated peritoneal vascular permeability in mice (23.3 and 33.4% inhibition, respectively) at 20 and 40 mg/kg.
Significantly decreased the leukocytes in the mice peritoneal cavity induced by CMC–Na at all the tested doses (46.0, 49.1, and 58.7% inhibition, respectively).
Markedly prolonged the pain latency at 20 and 40 mg/kg and decreased the writhing counts at 40 mg/kg (49.7% inhibition) in acetic acid (HY-Y0319)-induced writhing test in mice. However, it did not obviously improve the pain threshold of mice in hot-plate test.
Animal Model: Male Sprague Dawley (SD) rats (200-220 g) with skin wound model[4]
Dosage: 0.5 and 1.5 mg/kg
Administration: Topical application; twice a day; 8 days
Result: Promoted wound healing.
Reduced inflammatory infiltration.
Enhanced collagen deposition.
Upregulated the expression of CD31 and PCNA
Molecular Weight

498.53

Formula

C26H30N2O8
CAS No.
Appearance

Solid

Color

Off-white to yellow

SMILES

O=C1N2CCC3=C(NC4=C3C=CC=C4)[C@]2([H])C[C@]5([H])C1=CO[C@@H](O[C@H]6[C@@H]([C@H]([C@@H]([C@@H](CO)O6)O)O)O)[C@@H]5C=C
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (200.59 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.0059 mL 10.0295 mL 20.0590 mL
5 mM 0.4012 mL 2.0059 mL 4.0118 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (5.01 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (5.01 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.0059 mL 10.0295 mL 20.0590 mL 50.1474 mL
5 mM 0.4012 mL 2.0059 mL 4.0118 mL 10.0295 mL
10 mM 0.2006 mL 1.0029 mL 2.0059 mL 5.0147 mL
15 mM 0.1337 mL 0.6686 mL 1.3373 mL 3.3432 mL
20 mM 0.1003 mL 0.5015 mL 1.0029 mL 2.5074 mL
25 mM 0.0802 mL 0.4012 mL 0.8024 mL 2.0059 mL
30 mM 0.0669 mL 0.3343 mL 0.6686 mL 1.6716 mL
40 mM 0.0501 mL 0.2507 mL 0.5015 mL 1.2537 mL
50 mM 0.0401 mL 0.2006 mL 0.4012 mL 1.0029 mL
60 mM 0.0334 mL 0.1672 mL 0.3343 mL 0.8358 mL
80 mM 0.0251 mL 0.1254 mL 0.2507 mL 0.6268 mL
100 mM 0.0201 mL 0.1003 mL 0.2006 mL 0.5015 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Strictosamide Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Strictosamide23141-25-5ParasiteFungalNO SynthaseInterleukin RelatedNF-κBp38 MAPKNa+/K+ ATPasePERKJNKAktPI3KNitric oxide synthasesNOSILNuclear factor-κBNuclear factor-kappaBSodium potassium pumpProtein kinase R-like endoplasmic reticulum kinasePKR-like endoplasmic reticulum kinasec-Jun N-terminal kinasePKBProtein kinase BPhosphoinositide 3-kinaseAnti-inflammatorypainantiplasmodialantifungalskin wound modelRAW 264.7Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Strictosamide
Cat. No.:
HY-N1198
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB) Italian - IT (251 KB) Portuguese - PT (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.